Navigation Links
Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations
Date:12/4/2008

AMSTERDAM, December 4 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today that it has successfully completed treatment of the last patient on its ATIR(TM) phase I/II clinical trial. ATIR(TM), a donor lymphocyte cell based product, is under development to prevent acute Graft versus Host Disease (GvHD) and allow early immune reconstitution following a mismatched bone marrow transplantation. Nineteen end stage blood cancer patients were treated with no cases of grade III/IV acute GvHD occurring within the first 100 days after ATIR(TM) infusion, showing the feasibility and tolerability of the addition of ATIR(TM) in combination with a mismatched transplant procedure.

Following scientific advice from the EMEA Kiadis Pharma is preparing to initiate a multi center multinational pivotal study starting recruitment early 2009. In this study the efficacy of ATIR(TM) will be investigated in patients diagnosed with AML, ALL or MDS eligible for an allogeneic bone marrow transplantation but for whom no matching donor is available.

"Bone marrow transplantations are often the only treatment option left for end-stage blood cancer patients. But too many patients simply do not find a suitable matched donor in time" says Dr. Denis-Claude Roy of the Maisonneuve-Rosemont Hospital in Montreal, the principal investigator on the study. "Our study shows a rapid immune reconstitution in transplanted patients provided with ATIR(TM) treated immune cells from mismatched donors. Without ATIR(TM) treatment this would not be possible because of the high risk of acute Graft versus Host Disease with mismatched donor immune cells. This is obviously a very hopeful development for a large patient group."

Dr. Manja Bouman, CEO of Kiadis Pharma, says "The results of this clinical trial are very encouraging and it is another important milestone in the development of ATIR(TM) as a novel approach which may enable a safe an
'/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
2. Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
3. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
4. Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand
5. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
6. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
7. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
8. Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
9. Isogen Launches Major New Facility to Address Global Biopharma Demand
10. Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia
11. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... New-generation electronic designs are focused on ... Simultaneously, circuitry is increasing the number of functions ... it performs at. Connecting cables from the active ... such as cameras or detectors, must be small, ... include custom cable designs for high-quality signal and ...
(Date:6/18/2013)... Apama Medical, a privately held medical ... atrial fibrillation technologies, today announced the issuance of ... and Trademark Office (USPTO), titled "Low Profile Electrodes". ... use on expandable structures such as balloons used ... "We are grateful to the NSF SBIR ...
(Date:6/17/2013)... 2013 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... at ENDO 2013, the Endocrine Society,s 95 th ... (synchronize) both melatonin and cortisol rhythms. This effect ... body clock and address the circadian desynchrony which ... (Safety and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal ...
Breaking Medicine Technology:Omnetics Circular Connectors Offer Both Micro and Nano Interconnects for Highly Portable Electronic Systems, Meeting the Needs of Designers Looking for Size Reduction Options and Cable Flexibility 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4
... Inc . announced today that David A. Weber, Ph.D. , ... Board of Directors. Jay Lichter, Ph.D., managing director of Avalon Ventures, ... actively support the company as a member of the Board of ... to the Otonomy team, as his extensive experience in the development ...
... 2010 Amicus Therapeutics (Nasdaq: FOLD ), ... diseases, today announced that it has been awarded a ... Parkinson,s Research (MJFF) for the development of a novel, ...  The $500,000 award will be distributed over a period ...
Cached Medicine Technology:Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 2Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 2Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 4Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 5
(Date:6/18/2013)... 2013 Daily Gossip Magazine has always kept ... useful articles. , The magazine has decided to prepare ... new anabolic recipe every week . , According ... perfect guide for readers who are looking to get insights ... Gossip reveals that anabolic food is almost entirely based on ...
(Date:6/18/2013)... SEATTLE, WA (PRWEB) June 18, 2013 ... against Townsend Farms of Fairview, Oregon, claiming he fell ... company’s frozen berry and pomegranate seed blend. The ... No. 13-2-05597-8) by Marler Clark, the Seattle-based law firm ... Farms .[1] , According to the complaint, Brian Brothers ...
(Date:6/18/2013)... The Temp1000IS temperature data logger ... can be used to automatically record temperatures between -20 ... Temp1000IS comes with the serial number and device name ... (sold separately) docking station and can be placed directly ... removal of end-caps to download data. The small size ...
(Date:6/18/2013)... June 18, 2013 Senior drug regulatory officials ... June 25 to discuss—for the first time in the U.S.—the ... drugs through the regulatory process in a timely manner. Representatives ... will share respective best practices and processes in drug review ... panel at the DIA 2013 49th Annual Meeting ...
(Date:6/18/2013)... Palo Alto, CA (PRWEB) June 18, 2013 ... to be one of America's greenest cities with its recent ... City Council authorized three major solar electric power purchase ... up to 182,500 megawatt-hours (MWh) of solar photovoltaic electric power ... of the City’s electric needs. That’s enough power to ...
Breaking Medicine News(10 mins):Health News:Anabolic Cooking Book Review Exposes Dave Ruel’s Top 10 ‘Anabolicious’ Recipes for BodyBuilders 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 3Health News:MadgeTech, Inc. Introduces the New Temp1000IS Intrinsically Safe High Temperature Data Logger 2Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 2Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 3
... plans that give best value for money, study finds , ... aren,t implementing strategies and programs to improve the quality and ... in the Nov. 21 issue of the Journal of ... Health researchers surveyed 609 executives of the largest employers ...
... Inc. (TSX: DDS;,NASDAQ: DDSS) today announced that it ... and Drug Administration (FDA) regarding its appeal of ... through,the Formal Dispute Resolution process. In the response, ... II, Center for Drug Evaluation and,Research has not ...
... Sullivan,s industry research concludes, ,Masimo pulse oximetry is ... sign module clinicians ask for by brand, IRVINE, ... Pulse CO-Oximetry and Read-Through Motion and Low,Perfusion pulse oximetry, ... Best Practices Award, for Pulse Oximetry Leadership -- "ranking,number ...
... 20 NNN Healthcare/Office REIT,Inc. has acquired ... 15, 2007. Northmeadow Medical Center is ... the Atlanta suburb of Roswell,Georgia. Built in ... is,strategically located directly across the street from ...
... 20 CHF,International has been selected as the ... Fund) new Principal Recipient (PR) for,HIV/AIDS prevention, treatment ... awarded an HIV proposal in Round 3 programming., ... years, CHF will be directly responsible for,managing Honduras, ...
... Ga., Nov. 20 Immucor, Inc. (Nasdaq:,BLUD), a ... blood transfusion industry, announced today that Richard A. ... and Chief Financial Officer,effective December 10, 2007. The ... to resign for family reasons but had agreed ...
Cached Medicine News:Health News:Most U.S. Companies Do Little to Boost Worker Health Benefits 2Health News:Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol 2Health News:Masimo Corporation Receives a Frost & Sullivan 2007 Industry Best Practices Award for Pulse Oximetry Leadership 2Health News:Masimo Corporation Receives a Frost & Sullivan 2007 Industry Best Practices Award for Pulse Oximetry Leadership 3Health News:Masimo Corporation Receives a Frost & Sullivan 2007 Industry Best Practices Award for Pulse Oximetry Leadership 4Health News:NNN Healthcare/Office REIT Acquires Northmeadow Medical Center in Roswell, Georgia 2Health News:NNN Healthcare/Office REIT Acquires Northmeadow Medical Center in Roswell, Georgia 3Health News:CHF International Named Global Fund Principal Recipient in Honduras 2Health News:Immucor, Inc. Appoints New Chief Financial Officer 2
Inquire...
Inquire...
... Anatomical Malar I Implants - Providing ... implant follows the contour of the zygoma ... prominence. Anatomical Malar II Implants - ... the surgeon with another augumentation option that ...
... - Anatomically designed to enhance the chin contour, ... mandible with a high-profile central chin projection. ... entire mandible, this implant provides a high central ... arms. Cleft Chin Implants - Designed with ...
Medicine Products: